Takeda Pharmaceutical Company Limited (TAK)
| Market Cap | 48.34B +2.2% |
| Revenue (ttm) | 28.34B -1.7% |
| Net Income | 1.21B +77.7% |
| EPS | 0.75 +78.0% |
| Shares Out | 1.58B |
| PE Ratio | 40.08 |
| Forward PE | 49.65 |
| Dividend | $0.25 (1.61%) |
| Ex-Dividend Date | Sep 30, 2025 |
| Volume | 2,442,725 |
| Open | 15.77 |
| Previous Close | 15.42 |
| Day's Range | 15.52 - 15.77 |
| 52-Week Range | 12.99 - 18.90 |
| Beta | 0.09 |
| Analysts | Strong Buy |
| Price Target | 20.74 (+32.69%) |
| Earnings Date | Jul 29, 2026 |
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enan... [Read more]
Financial Performance
In fiscal year 2026, Takeda Pharmaceutical's revenue was 4.51 trillion, a decrease of -1.66% compared to the previous year's 4.58 trillion. Earnings were 191.76 billion, an increase of 77.68%.
Financial numbers in JPY Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for TAK stock is "Strong Buy." The 12-month stock price target is $20.74, which is an increase of 32.69% from the latest price.
News
Takeda Releases New Positive Phase 3 FirstLight And RadiantLight Data For Oveporexton In Narcolepsy
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK), a pharmaceutical company, on Monday reported new data from the Phase 3 FirstLight and RadiantLight trials for Oveporexton in treating Type 1 Na...
Takeda presents additional results from oveporexton studies at SLEEP 2026
Takeda (TAK) presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton, an oral orexin receptor 2-selective agonist, improved daily functioning as well as cognitive and ...
New Pivotal Study Data Show Takeda's Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin re...
Takeda announces results for Phase 3 study of TAK-279
Takeda (TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib, TAK-279, an investigational, next-generation, highly selective and p...
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Japan's Takeda Pharmaceutical said on Thursday its experimental once-daily psoriasis pill, developed with the help of AI, outperformed Bristol Myers Squibb's approved drug Sotyktu in a late-stage hea...
Takeda's Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-...
FDA Accepts Takeda's SBLA For ENTYVIO IV In Pediatric UC And Crohn's Disease; PDUFA Set In Q1,2027
(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK) announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application or sBLA for intravenous ENTY...
FDA accepts Takeda’s application for intravenous Entyvio
Takeda (TAK) announced the U.S. Food and Drug Administration has accepted for review its supplemental Biologics License Application for intravenous ENTYVIO for the treatment of moderately to severely ...
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Appl...
Takeda Pharmaceutical Company Transcript: Jefferies Global Healthcare Conference 2026
Leadership transition is underway with Julie Kim as CEO, supported by a refreshed executive team and board. Three major product launches are expected to drive growth, while a transformation plan aims for significant cost savings and improved margins. ENTYVIO and plasma-derived therapies remain key revenue drivers amid evolving market dynamics.
Takeda Pharmaceutical Co Ltd (TAK) Shares Fall 4.8% -- GF Value Says Still Overvalued
Takeda Pharmaceutical Co Ltd (TAK) Shares Fall 4.8% -- GF Value Says Still Overvalued
Takeda Pharmaceutical is Now Oversold (TAK)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Takeda Ordered To Pay $884.9 Mln In AMITIZA Antitrust Case; To Revise FY25 Results
(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK) said Tuesday a jury in the U.S. District Court for the District of Massachusetts returned a verdict against the company in the AMITIZA or lubiprostone ...
Takeda Pharmaceutical (TAK) Found Guilty in Generic Drug Delay Conspiracy
Takeda Pharmaceutical (TAK) Found Guilty in Generic Drug Delay Conspiracy
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
BOSTON--(BUSINESS WIRE)---- $TAK #antitrust--A class-action lawsuit regarding Amitiza ended today when a jury found Takeda Pharmaceuticals liable for $474 million, according to Hagens Berman.
Jury finds Takeda caused about $885M in damages over generic delay, Reuters says
A U.S. jury on Monday determined that Takeda (TAK) Pharmaceutical caused pharmacies, insurers, retailers, and others to sustain roughly $885M in damages by postponing the release of a generic version…
Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
A U.S. jury on Monday found that Takeda Pharmaceutical caused pharmacies, insurers, retailers and others to sustain about $885 million in damages delaying the release of a generic version o...
Takeda told to pay hundreds of millions for generic drug delay, Bloomberg says
A federal jury in the U.S. District Court for the District of Massachusetts found Takeda (TAK) Pharmaceuticals liable for violating antitrust law by delaying the generic version of its branded…
Takeda ordered by pay hundreds of millions in antitrust case, Bloomberg says
14:25 EDT Takeda (TAK) ordered by pay hundreds of millions in antitrust case, Bloomberg says
Full Year 2026 Takeda Pharmaceutical Co Ltd Earnings Presentation Transcript
Full Year 2026 Takeda Pharmaceutical Co Ltd Earnings Presentation Transcript
Takeda Pharmaceutical Q4 Earnings Call Highlights
Takeda Pharmaceutical NYSE: TAK reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around thr...
Justice Department announces $13.67M civil settlement with Takeda
The Department of Justice said Takeda (TAK) Pharmaceuticals has agreed to pay $13.67M to resolve allegations that it “knowingly caused the submission of false claims to Medicare and other federal…
Takeda Pharmaceutical (TAK) Announces Global Restructuring with Job Cuts
Takeda Pharmaceutical (TAK) Announces Global Restructuring with Job Cuts
Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring
Japan's Takeda Pharmaceutical , plans to cut about 4,500 jobs in fiscal year 2026, as it pushes ahead with a restructuring to centralize corporate functions and reduce costs.
Takeda (TAK) Preserved FY2025 Margins, but FY2026 Now Depends on the Launch Pipeline
Takeda Pharmaceutical (TAK) delivered what investors needed from fiscal 2025: enough cost control and cash generation to offset a tougher... The post Takeda (TAK) Preserved FY2025 Margins, but FY2026 ...